Atividade anti-inflamatória e antinociceptiva de 4-((1-fenil-1h-pirazol-4-il) metil) piperazina-1-carboxilato: um novo derivado piperazínico

• Ano de defesa: 2015
• Autor(a) principal: Silva, Daiany Priscilla Bueno da
• Orientador(a): Costa, Elson Alves
• Banca de defesa: Costa, Elson Alves, Vanderlinde, Frederico Argollo, Menegatti, Ricardo
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Goiás
• Programa de Pós-Graduação: Programa de Pós-graduação em Biologia (ICB)
• Departamento: Instituto de Ciências Biológicas - ICB (RG)
• País: Brasil
• Palavras-chave em Português: Efeito antinociceptivo; Efeito anti-inflamatório; Derivados piperazínicos; LQFM-008; Via serotoninérgica
• Palavras-chave em Inglês: Antinociceptive effect; Anti-inflammatory effect; Piperazines derivatives; LQFM-008; Pathway serotonergic
• Área do conhecimento CNPq: BIOQUIMICA::BIOLOGIA MOLECULAR
• Link de acesso: http://repositorio.bc.ufg.br/tede/handle/tede/5497

The piperazines derivatives are an important class of chemical compounds with a broad spectrum of biological activities such as anti-infectious activity, anti-carcinogenic, anti-nociceptive, anti-hypertensive, anxiolytic and vasorelaxant and are attractive candidates for development of new analgesics and anti-inflammatories drugs. The aim of this study was evaluate the effects of piperazine compound LQFM-008 (4-[(1-phenyl-1H-pyrazol-4-yl) methyl]1-piperazine carboxylic acid ethyl ester) in acute tests of nociception and inflammation and characterize that the mechanisms are involved in the antinociceptive effect. For this study were used male mice weighing between 25 and 35g. In the formalin test, the treatments with LQFM-008 at doses of 48 and 96 μmol/kg (p.o.) reduced the licking time at both neurogenic and inflammatory phases of this test. The anti-inflammatory activity was confirmed, since LQFM-008 at doses of 48 and 96 μmol/kg (p.o.) reduced the formation of paw edema induced by carrageenan at all hours of the test and LQFM-008 in pleurisy test at dose of 96 μmol/kg (p.o.) also reduced leukocyte migration and protein exudation. In the tail-flick and the hot plate tests, the treatment with LQFM-008 at doses of 48 and 96 μmol/kg (p.o.) increased the latency to thermal stimulus, suggesting the involvement of central mechanisms in the antinociceptive effect LQFM-008. The pre-treatment of animals with naloxone (7.5 μmol/kg s.c.) reversed the antinociceptive effect of LQFM-008 only in the first phase of the formalin test, however, the pre-treatment with NAN-190 (1.3 μmol/kg i.p.) and PCPA (500 μmol/kg i.p.) reversed the antinociceptive effect of LQFM-008 in both phases of the test. Thus, the piperazine derivative LQFM-008 exhibit antinociceptive and anti-inflammatory activities in acute test and the antinociceptive effect is resulting from a central action with involvement of opioid receptors and the serotonin pathway.